Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 1912-1920

  Saez Llorens X ^a   Yogev, R ^b   Arguedas, A ^c   Rodriguez, A ^d   Spigarelli, M G ^e   De Leon Castrejon T ^f   Bomgaars, L ^g   Roberts, M ^h   Abrams, B ^h   Zhou, W ^h   Looby, M ^h   Kaiser, G ^h   Hamed, K ^h  

^a Hospital del Nino   (Panama)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Instituto de Atencion Pediatrica Costa Rica   (Costa Rica)

^d Hospital Infantil de Infectología y Rehabilitación   (Guatemala)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f Hospital Materno Infantil José Domingo de Obaldía   (Panama)

^g TEXAS CHILDREN S HOSPITAL   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 DEOXYPENCICLOVIR; FAMCICLOVIR; PENCICLOVIR; SWEETENING AGENT;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; CELLULITIS; CHILD; CLINICAL TRIAL; CLUMSINESS; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FLATULENCE; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; SINGLE DRUG DOSE; SYMPTOM; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; VOMITING;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; CHICKENPOX; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HERPES SIMPLEX; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; MALE; SIMPLEXVIRUS; TREATMENT OUTCOME;

EID: 66149141376     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01054-08     Document Type: Article

References (25)

1. Angelilli, M. L., M. Toscani, D. Matsui, and M. J. Rieder. 2000. Palatability of oral antibiotics among children in an urban primary care center. Arch. Pediatr. Adolesc. Med. 154:267-270. (Pubitemid 30131908)
2. Aoki, F. Y., S. Tyring, F. Diaz-Mitoma, G. Gross, J. Gao, and K. Hamed. 2006. Single-day, participant-initiated famciclovir therapy for recurrent genital herpes: a randomized, double blind, placebo trial. Clin. Infect. Dis. 42:8-13.
3. Balfour, H. H., Jr., B. Bean, O. L. Laskin, R. F. Ambinder, J. D. Meyers, J. C. Wade, J. A. Zaia, D. Aeppli, L. E. Kirk, A. C. Segreti, and R. E. Keeney. 1983. Acyclovir halts progression of herpes zoster in immunocompromised participants. N. Engl. J. Med. 308:1448-1453.
4. Bartelink, I. H., C. M. A. Rademaker, A. F. A. M. Schobben, and J. N. van den Anker. 2006. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. 45:1077-1097. (Pubitemid 44631388)
5. Breuer, J., and R. Whitley. 2007. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 14(Suppl. 2):25-29. (Pubitemid 47605617)
6. Carcao, M. D., R. C. Lau, A. Gupta, H. Huerter, K. Gideon, and S. M. King. 1998. Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocompromised children. Pediatr. Infect. Dis. J. 17:626-631. (Pubitemid 28340875)
7. Gill, K. S., and M. J. Wood. 1996. The clinical pharmacokinetics of famciclovir. Clin. Pharmacokinet. 31:1-8. (Pubitemid 26238199)
8. Laskin, O. L. 1983. Clinical pharmacokinetics of acyclovir. Clin. Pharmacokinet. 8:187-201. (Pubitemid 13134065)
9. Luck, S., M. Sharland, P. Griffiths, and S. M. Jenkins. 2006. Advances in the antiviral therapy of herpesvirus infection in children. Expert Rev. Anti- Infect. Ther. 4:1005-1020. (Pubitemid 46040352)
10. Nadal, D., G. Leverger, M. E. Sokal, D. Floret, Y. Perel, K. Leibundgut, and S. Weller. 2002. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J. Infect. Dis. 186:S123-S130. (Pubitemid 35178859)
11. Pue, M. A., and L. Z. Benet. 1993. Pharmacokinetics of famciclovir in man. Antivir. Chem. Chemother. 4(Suppl. 1):47-55. (Pubitemid 24000501)
12. Pue, M. A., S. K. Pratt, A. J. Fairless, S. Fowles, J. Laroche, P. Georgiou, and W. Prince. 1994. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. 33:119-127.
13. Sacks, S. L., F. Y. Aoki, A. Y. Martel, S. D. Shafran, and M. Lassonde. 2005. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin. Infect. Dis. 41:1097-1104. (Pubitemid 41429471)
14. Saral, R., R. F. Ambinder, W. H. Burns, C. M. Angelopulos, D. E. Griffin, P. J. Burke, and P. S. Lietman. 1983. Acyclovir prophylaxis against herpes simplex virus infection in participants with leukemia. A randomized, double blind, placebo-controlled study. Ann. Intern. Med. 99:773-776.
15. Saral, R., W. H. Burns, O. L. Laskin, G. W. Santos, and P. S. Lietman. 1981. Acyclovir prophylaxis of herpes simplex virus infections. N. Engl. J. Med. 305:63-67.
16. Schwartz, R. H. 2000. Enhancing children's satisfaction with antibiotic therapy: a taste study of several antibiotic suspensions. Curr. Ther. Res. 61:570-581.
17. Shen, M. C., H. H. Lin, S. S. Lee, Y. S. Chen, P. C. Chian, and Y. C. Liu. 2004. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in participants with uncomplicated herpes zoster. J. Microbiol. Immunol. Infect. 37:75-81. (Pubitemid 38828589)
18. Simpson, D., and K. A. Lyseng-Williamson. 2006. Famciclovir. A review of its use in herpes zoster and genital and orolabial herpes. Drugs 66:2397-2416.
19. Spruance, S. L., N. Bodsworth, H. Resnick, M. Conant, C. Oeuvray, J. Gao, and K. Hamed. 2006. Single-dose, participant-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J. Am. Acad. Dermatol. 55:47-53.
20. Tyring, S., R. Belanger, W. Bezwoda, P. Ljungman, R. Boon, and R. L. Saltzman. 2001. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised participants. Cancer Investig. 19:13-22. (Pubitemid 32233797)
21. Vinh, D. C., and F. Y. Aoki. 2006. Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opin. Pharmacother. 7:2271-2286.
22. Watson, B. M., J. A. Foster, C. J. White, and D. Laufer. 1996. Varicella in the normal and immunocompromised host. Baillieres Clin. Infect. Dis. 3:425-438. (Pubitemid 26417632)
23. Weller, S., M. R. Blum, M. Doucette, T. Burnette, D. M. Cederberg, P. de Miranda, and M. L. Smiley. 1993. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther. 54:595-605. (Pubitemid 24028442)
24. West, G. B., J. H. Brown, and B. J. Enquist. 1997. A general model for the origin of allometric scaling in biology. Science 276:122-126. (Pubitemid 27161259)
25. Whitley, R. J. 2008. Therapy of herpes virus infections in children. Adv. Exp. Med. Biol. 609:216-232.